Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

India's Alembic Pharma Forms JV to Market Generics in China

publication date: May 8, 2019

To promote its generic products in China, Alembic Pharma of India announced a China joint venture with China's SPH SINE Pharma and Adia (Shanghai) Pharma. SPH Sine will hold 51% of the JV, Alembic 44% and Adia 5%. The JV will be funded with $150 million in equity, contributed by the three partners proportionately. The partners expect the JV to eventually establish a manufacturing facility in China. Until then, Alembic will supply the JV with products from its India manufacturing plants. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital